YoungHeartValve

Polymeric TAVR Heart Valve Technology

health AI/biotech medtech—cardiovascular devices (TAVR)

Visit website LinkedIn ↗

Stagepre-seed/seed (SBIR-funded)

Raised$6.5 million

Employees5

LocationAtlanta, GA

About

YoungHeartValve's market-disruptive, durable biopolymeric technology, with worldwide exclusive rights, is poised to set a new standard for the growing market of low-risk patients.

Product

Value proposition: Tissue-free, hyaluronan-enhanced polymer leaflets designed to resist thrombosis and calcification with scalable, animal-free manufacturing for multiple valve indications

Founders

Lakshmi Prasad Dasi, Ph.D. — Co-Founder and CTO
Susan James, Ph.D. — Co-Founder and COO

Products

Biopolymer Leaflet TAVR Valve

Key features

Biopolymer leaflets built for enduranceBalloon expandable, low-profile deliveryProprietary dynamic sealing technology to reduce paravalvular leakageScalable manufacturing without animal tissueHylauronan-enhanced polymer technology for thrombosis/calcification resistance

Technologies

Hylauronan-enhanced polymer leafletsTAVR (transcatheter aortic valve replacement)Dynamic sealing technologySynthetic, animal-free manufacturingInterpenetrating network biomaterial

Traction metrics

3 patents approved or pending in US and worldwideNIH SBIR Phase 1 fundraising (raised $450K)

Investors

National Institutes of Health (NIH) (via SBIR grants)